By Our Reporter,The Nation
Copyright thenationonlineng
Twenty-nine years ago, the 2025 recipient of the Sheiner-Beal award was at the ASCPT 1996 Annual Meeting. Dr. Ette was presenting a paper when Dr. Lewis Sheiner approached him and complimented his work. Moments of recognition, both big and small, shape and inspire careers. ASCPT’s scientific awards recog- nize excellence in the field and inspire future excellence for years to come.
Since the first Oscar B. Hunter Award was given to Dr. Jonas Salk in 1955, the ASCPT Scientific Awards have recognized over 300 extraordinary researchers, clinicians, teachers, leaders, volun- teers, and students. The 11 different awards recognize excellence over the career spectrum and in a diverse array of focus areas. For instance, the Rawls-Palmer Progress in Medicine Award aims to in- corporate the efforts of modern research in patient care and to help bridge the gap between the results of research and its application in patient care. Meanwhile, the Malle Jurima-Romet Mid-Career Leadership Award recognizes exceptional leadership and outstand- ing contributions to clinical pharmacology by a mid-career clinical pharmacologist and encourages continued leadership and future impactful scientific contributions. Learn about the other nine awards on our website (https://www.ascpt.org/Member-Services/ About-ASCPT/ASCPT-Awards).
Nominations close Thursday, July 24, 2025! Please note that you can work with up to five other colleagues on a nomination packet! Additionally, the primary nominator can confirm the support of all co-nominators in the submission site, removing the need to collect signatures for the letter of support. Check ascpt.org (https://www. ascpt.org/Member-Services/About-ASCPT/ASCPT-Awards) to learn more about all the different ASCPT Scientific awards and nominate a worthy colleague for the recognition they deserve!
Low-to-Middle-Income Country Accelerator Program Call for Applications
ASCPT is pleased to announce the call for applications for the second cohort of the Low-to-Middle-Income Country (LMIC) Accelerator Program. First launched in 2023, the LMIC Accelerator fosters the participation of LMIC clinical pharmacol- ogists and translational scientists at the ASCPT Annual Meeting, enabling global collaboration, knowledge exchange, and commu- nity engagement.
The Society will welcome 10 (10) LMIC clinical pharmacol- ogists and translational scientists to the 2025–2026 cohort who will each be provided a $7500 USD grant to travel and attend the 2026 Annual Meeting to be held March 4–6, 2026, in Denver, Colorado. In addition to attending the 2026 Annual Meeting in person, participants will be assigned an ASCPT mentor and join ASCPT for quarterly virtual networking sessions. Submit your application via the online submission site by July 18, 2025, to be considered.
Requirements
The recipient must be a member of ASCPT at the time the grant is used.
Applicants must reside in a World Bank classified LMIC coun- try. See https://data.worldbank.org/country/XO.
Applicants from within all career stages and employment back- grounds will be considered.
Applications
Applications should include the following:
A cover letter summarizing the applicant’s qualifications within clinical pharmacology or translational science along with a brief overview of how participation at the ASCPT Annual Meeting will impact their work and growth in the field. Applicants should include how learning from the Annual Meeting can be applied to the work they do within their organization.
Confirmation that the applicant acknowledges that it is their responsibility to secure a Visa in advance of making travel arrangements if selected.
Applicant’s curriculum vitae.
Additional considerations for the LMIC Travel Grant are avail- able on the ASCPT website.
ASCPT is pleased to offer an LMIC membership category with a reduced rate of $50 USD for 1 year or $90 USD for 2 years. Contact [email protected] with your first name, last name, or- ganization/institute, and country of residence, or visit the ASCPT website for the PDF membership application.
The LMIC Travel Grant Program and membership category reflect ASCPT’s commitment to diversity, equity, and inclusion and support the Society’s mission and vision to advance clinical pharma- cology for the benefit of patients and society on a global level.
Questions about the LMIC Accelerator Program and applica- tion submission can be sent to [email protected].
Now Accepting Applications: 2025–2026 Editors-in- Training for the ASCPT Journal Family
The ASCPT Journal Family is excited to open the call for applica- tions for the 2025–2026 Editor-in-Training (EIT) term! Since its launch in 2019, the EIT program has offered early career scientists a one-of-a-kind opportunity to join the editorial teams of Clinical Pharmacology & Therapeutics (CPT), CPT: Pharmacometrics & Systems Pharmacology (PSP), and Clinical and Translational Science (CTS).
As an EIT, you’ll gain hands-on experience in the editorial pro- cess—including peer review and decision-making—contribute to strategic planning efforts, and receive one-on-one mentorship from senior editors. You’ll also help shape the journals’ social media strategy and engage with the ASCPT Early Career Community, building on the initiatives of prior EIT cohorts. Midway through the term, you’ll have a chance to connect with journal leadership to reflect on progress and explore new opportunities for growth.
Who Should Apply?
Each journal will select 1–2 EITs through an independent search. Ideal candidates are early-career scientists (within the first 5 years of professional practice) with at least 1 year of experience in clini- cal pharmacology, translational science, pharmacometrics, systems pharmacology, or related fields.
We’re looking for individuals who are:
Passionate about advancing science, patient care, and scholarly publishing.
Strong communicators with a solid track record of publications and peer review (relative to career stage).
Active members of ASCPT or prepared to join if selected.
Engaged in the Early Career Community or similar networks.
Ready to elevate the journals’ digital presence and social media reach.
No prior editorial experience is required—just enthusiasm, a collab- orative mindset, and a commitment to learning. Please note that this is a 1-year educational opportunity and is not a compensated position.
How to Apply
Submit your CV and a one-page letter of interest (specifying your journal of choice) to Alaina Webster at [email protected] by COB, June 20, 2024.
Please note: applicants may apply to only one journal, and indi- viduals currently enrolled in the Leadership Accelerator Program are not eligible.
Commitment to Diversity, Equity, and Inclusion
ASCPT and the Journal Family are committed to fostering a di- verse, equitable, and inclusive environment. We believe that di- verse perspectives strengthen our work and our community. We strongly encourage individuals from historically underrepresented groups to apply. Read ASCPT’s full DEI statement here: https:// www.ascpt.org/Member-Services/About-ASCPT/ASCPT-State ment-on-Diversity-Equity-and-Inclusion
For more information, contact Alaina Webster at [email protected].
ASCPT Leadership Accelerator Program: Empowering the Next Generation of Leaders
The ASCPT Leadership Accelerator Program is an 18-month, immersive experience designed to support early career profession- als in developing leadership skills and gaining a comprehensive understanding of the Society’s inner workings. Running from September 2025 to March 2026, this program offers a unique opportunity to engage with ASCPT’s Governance, Membership, Education, and Journals divisions.
As a participant, you will:
Be matched with an experienced, engaged ASCPT mentor
Join an ASCPT committee or taskforce and contribute to on- going initiatives.
Receive an exclusive invitation to attend the Fall 2023 Board of Directors meeting virtually.
Participate in custom-designed webinars led by ASCPT leaders and key staff.
You’re an ideal candidate if you:
Have at least 1 year of professional experience in clinical phar- macology, translational science, pharmacometrics, systems pharmacology, or a related field.
Are passionate about advancing science, supporting patients, drug discovery and development, and fostering equity in STEM.
Have demonstrated service to or engagement with ASCPT.
Are ready to grow your leadership skills and deepen your in- volvement in the Society.
To be considered for the next Leadership Accelerator cohort, please send your CV and a one-page letter of interest to Alaina Webster at [email protected] by COB, Friday, June 27, 2025.
Want a closer look at the program? Watch the Leadership Accelerator webinar to hear from program architects and past participants.
Additional information can be obtained from Alaina Webster at [email protected].
Board Nominations Coming Soon!
Did you know that ASCPT is governed by a Board of 11 members? ASCPT members just like you? ASCPT’s Board of Directors is made up of clinical pharmacologists and transla- tional scientists from a diverse array of academic backgrounds, demographics, focus areas, and even employment sectors. These strategic thinkers volunteer their time and work together to serve the members of ASCPT and the field of clinical pharma- cology as a whole!
Being a member of the Board stands out in one’s career, and not just as a resume builder. Former At-Large Board Member Donald Heald, PhD, points to his time on the Board as his fondest ASCPT memory! He found working with the other Board members to make strategic and impactful decisions both challenging and personally rewarding. Former At-Large Board Member and past President of ASCPT Susan Abdel-Rahman, PharmD, is grateful for her time on the Board and the opportunity to work closely with so many insightful members!
This year, the Board is filling the following positions: President- Elect, three (3) At-Large Directors, and one (1) Student/Trainee member. Check out the ASCPT website for more information (https://www.ascpt.org/Member-Services/About-ASCPT/ Governance-Board/Board-Nominations). If you have any ques- tions, reach out to [email protected].
Opening Doors for the Benefit of Patients and Society on a Global Level
This year was the inaugural year for the ASCPT Low- to Middle- Income Country (LMIC) Accelerator Program. This new program promotes diversity, equity, and inclusion in global health forums and fosters collaboration across different sectors and regions. The program enables LMIC scholars and scientists to participate in ASCPT’s dynamic network of global clinical pharmacologists and translational scientists throughout the year through quarterly virtual events and in person at the ASCPT Annual Meeting.
The 10 LMIC scholars in the program were able to participate at the ASCPT Annual Meeting with the support of travel grants. These travel grants have been funded through the generous con- tributions of donors who support ASCPT. With your support, we can keep this program active for years to come and truly promote knowledge exchange and collaboration by facilitating the sharing of research and best practices, thereby fostering collaborations that can drive advancement in clinical pharmacology globally.
From our website (https://www.ascpt.org/Resources/Donat ions) you can donate to this wonderful grant program and others. Questions about the LMIC Accelerator Program can be directed to ASCPT’s COO, Elise Laffman-Johnson, at [email protected]. Thank you in advance for your generosity!
Get in Front of the Right Audience!
Are you ready to showcase your clinical pharmacology and trans- lational science research to the field’s most influential audience? ASCPT will soon be accepting abstract submissions for poster ses- sions at the ASCPT 2026 Annual Meeting to be held March 4–6 in Denver, Colorado.
The poster sessions consistently rank among attendees’ favor- ite meeting activities, creating an interactive environment where
groundbreaking research meets constructive feedback. Each year, these vibrant sessions foster countless collaborations and spark dis- cussions that advance our discipline.
Why present your work at our meeting? Your research de- serves visibility among the right audience. Our attendees in- clude leading experts in clinical pharmacology and translational science, potential collaborators seeking innovative partners, ASCPT journal family editors scouting for research to publish, and employers looking for new talent to add to their teams from across academic, industry, and regulatory sectors. Interactions in the poster hall have led to collaborations, job opportunities, publication invitations, lifelong friendships, important lessons, and much more! This concentrated gathering of key stakehold- ers makes our Annual Meeting an unparalleled opportunity for research exposure and career advancement.
Attended Poster sessions offer an ideal format for receiving de- tailed one-on-one feedback on your work in a collegial setting. Many of our most successful members trace their own critical re- search partnerships and publication opportunities back to connec- tions they made during these sessions. Whether you are presenting preliminary findings, completed studies, or novel methodologies, our poster sessions are the perfect platform to enhance your re- search impact and professional network.
Don’t miss this opportunity to join the scientific conversation at what promises to be our most dynamic meeting yet. Submissions are opening soon—but mark your calendars, they close September 12, 2025. Questions about abstract submission can be directed to [email protected].
I Am ASCPT Member Profiles
Babatunde Ayodeji Adeagbo, PhD, Senior Lecturer, Obafemi Awolowo University, Osun State, Nigeria
What does being an LMIC Accelerator Cohort Member mean to you?
Being a low- to middle-income country
(LMIC) Accelerator Cohort Member is an incredible opportunity for me. It signifies a privilege to join a community of researchers in clinical phar- macology. It is a rare opportunity to reinforce my commitment to advancing global health research and translating findings into meaningful impact in LMICs. It is a chance to connect with a di- verse network of passionate and talented individuals, learn from experienced mentors, and contribute to innovative solutions for pressing health challenges.
What are you looking forward to in your time as part of the LMIC Accelerator Cohort?
I am looking forward to developing strong collaborations by connecting with other cohort members to share experiences and challenges. This program will provide a platform for me to build lasting partnerships to address complex research ques- tions. I am looking forward to gaining valuable mentorship. I am looking forward to learning from seasoned researchers and leaders in global health, gaining insights into successful project implementation and career development. I am looking forward to improving my research skills. I am looking forward to en- hancing my knowledge and expertise in areas like grant writing, data analysis, leadership skills, and project management. I am also looking forward to contributing to impactful research. I look forward to conducting high-quality research that addresses critical health needs in LMICs and contributes to improving health outcomes.
What is the most important leadership lesson you have learned the hard way?
The most important leadership lesson I have learned the hard way
is the importance of empathy and active listening. I have realized that effective leadership requires understanding the perspectives and needs of your team members and actively listening to their concerns and ideas. Building trust and fostering a supportive envi- ronment are crucial for success.
What was your childhood dream job?
From a young age, I was fascinated by the human body and the intricate workings of disease. I remember vividly watching doc- umentaries about groundbreaking medical discoveries and the tireless efforts of scientists to improve human health. These images instilled in me a deep desire to contribute to something meaningful, to make a real difference in the world. My childhood dream was to become an international independent research leader in translational pharmaceutical science. I envisioned a career dedicated to bridging the gap between the bench and the clinic, where cutting-edge research translates into tangible im- provements in people’s lives in low- and middle-income coun- tries. I dreamed of tackling emerging health problems unique to these settings, from infectious diseases to non-communicable conditions, and developing innovative solutions. I envisioned es- tablishing a center of excellence where a multidisciplinary team of researchers could collaborate, conduct cutting-edge research, and train the next generation of global health leaders. This dream, though ambitious, fueled my passion for learning. It drove me to excel in my studies, to seek out challenging research experiences, and to develop a deep understanding of the com- plexities of global health. I am constantly inspired by the dedica- tion of researchers and clinicians working tirelessly to improve the health of underserved populations. This dream continues to guide my career path, reminding me of the importance of pursu- ing research that has a real-world impact and the power of col- laboration to address the most pressing global health challenges.
How do you keep focused and motivated?
I stay focused and motivated when I have a goal that I am pursu- ing. Moreover, anything that aligns with my passion and interests motivates me. Whenever I see that what I am doing is having an impact on people, my community, and the lives of others, I feel a greater sense of commitment and motivation.
Dr. Adeagbo has been a member of ASCPT since 2024.
Jin Yan JinJin Yan Jin, PhD, Executive Director and Senior Fellow, Global Head of Modeling and Simulation (M&S) and Ophthalmology/Neuroscience Clin Pharm (OMNI-ON), Genentech, Inc., South San Francisco, California
What does being an At-Large Board member mean to you?
It means that I have this invaluable opportunity to give back more to this Society that I “grew up” with and have benefited so much from. It means I can serve more members, speak for them, and support their needs. It means I can contribute my small building block toward the future of our Society.
What are you looking forward to in your role as an At-Large Board member?
As the ASCPT 2020–2025 Strategic Plan is finishing up, I am
most looking forward to the coming Strategic Planning during my tenure as a Board Member to pave the future of our Society. I am also looking forward to leveraging my scientific expertise and professional experience to support ASCPT’s unique strength in its multidisciplinary nature as a catalyst for clinical, translational, and predictive science.
Who has inspired you in your career?
Madame Curie—she is my childhood hero and has been an in- spiration throughout my career. I admire her as a very successful female scientist and working mother, receiving the Nobel Prize twice at a time when females were sparse in science, including receiving a second award after the sudden passing of her hus- band. She raised two girls on her own, including one who grew up to receive another Nobel Prize. As a working mother, also with two girls myself, she has inspired me in my career and in my life!
Do you have a favorite tip or trick for clinical practice or research that you want to share with fellow members?
Stay curious and be adaptive. Firstly, recognizing (and admitting)
what you do not know could be the best way to convince others and to lead.
What is one thing that people would be surprised to learn about you?
I am a Hello Kitty enthusiast—though this is probably known
by many of the people who know me and work with me. I have Hello Kitty on my phone, laptop, office door, and also throughout my home—toaster, oven, waffle maker, kettle, mini fridge… You name it!
Dr. Jin has been a member of ASCPT since 2010.
Jiawei Zhou, PhD, Assistant Professor, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
What does being a CPT:Pharmacometrics & Systems Pharmacology (PSP) Editor-in-Training mean to you?
This opportunity allows me to gain valuable insights into the decision-making processes of journal editors, including the factors they consider when accepting, rejecting, or requesting revisions. Additionally, it provides a platform for me to expand my professional network.
What is your favorite part of being a PSP Editor-in-Training? I can participate in the PSP editors’ monthly and quarterly meet- ings. At these meetings, I can observe the editorial team discuss future directions for PSP and select themes for special collections. This also provides an opportunity for me to introduce my research interests to PSP.
Do you have a favorite tip or trick for research that you want to share with fellow members?
Focus on the clinical question you aim to resolve and always remember to prioritize our patients.
What is one thing people would be surprised to know about you?
I am a Formula 1 racing fan, and my lifelong dream is to visit every F1 circuit and watch a live race at each one.
Dr. Zhou has been a member of ASCPT since 2016.
Ene I. Ette, PhD, President, Anoixus Corporation, Natick, Massachusetts
What does being the 2025 Sheiner- Beal Pharmacometrics Award Recipient mean to you?
Being named the 2025 Sheiner-Beal Pharmacometrics Award recipient is an ex- traordinary honor with deep personal and professional significance. This award represents not just a recog- nition of individual contributions to the field of pharmacometrics but also a validation of the collective impact of innovation, collab- oration, and dedication to advancing healthcare.
On a personal level, this accolade serves as a milestone in a jour- ney defined by resilience, determination, and a commitment to empowering patients through evidence-based decision-making. It underscores the importance of bridging the gap between science and practice—ensuring that pharmacometrics drives real-world benefits for diverse populations, particularly those underserved in healthcare.
Professionally, recognition reinforces the value of fostering interdisciplinary collaborations, promoting diversity in clinical research, and leveraging data to improve patient outcomes. It is a
moment to reflect on the progress we have made in making clini- cal research more accessible and inclusive while acknowledging the work that still lies ahead.
Ultimately, receiving this award is a reminder of the power of perseverance and the importance of aligning purpose with action. It inspires me to continue advocating for equitable healthcare and advancing innovative solutions that empower individuals to take an active role in their health journey.
What professional accomplishment are you most proud of? I thought about how we changed the duration of hepatitis C from 48 weeks with intron-based therapy to 24 weeks with telaprevir, thereby changing the hepatitis drug development and pharma- cotherapy landscape and paving the way for a shorter duration of treatment today. Although it was a significant accomplish- ment, its impact is limited to hepatitis C drug development and pharmacotherapy.
The professional accomplishment that I am MOST proud of is the 1999 US Food and Drug Administration Guidance for Industry: Population Pharmacokinetics, which was only revised in 2019. The guidance, which contained most of my research at the time on the de- sign and analysis of population pharmacokinetic studies, has changed how drugs are developed worldwide. It has led to data-driven drug development decision-making, and it is the basis for model-informed drug development and precision medicine.
What is the most important leadership lesson that you have learned the hard way?
I cannot recall a leadership lesson that I learned the hard way rather I will share some thoughts on successful leadership. Success as a leader is about the intersection of technical expertise and empow- ering others to excel and grow. As the head of an organization and previously a department head, I have learned that employees cannot reach their full potential without the provision of the necessary trust and learning environment. They need the room to make mistakes while learning, knowing that I am there for them and investing in their professional growth and development. Authentic leadership lies in inspiring others, creating a shared vision, and recognizing that the collective strength of a team often determines success. My career journey is underscored by the transformative power of hu- mility, collaboration, and a commitment to leave a lasting legacy in Pharmacometrics and Clinical Pharmacology.
What has been the greatest challenge in your career?
The greatest challenge has been maintaining a work/life balance. For me, my family comes first. Therefore, I always make it my priority to be there for my family. My family is my greatest asset in life.
Do you have a favorite tip or trick for clinical practice that you want to share with fellow members?
There are no shortcuts to excellence, but hard work and reading
widely is a good start. Open paths for others to tread instead of taking well-worn paths that everyone knows where they lead.
In research or practice, there are some key questions you need to ask, and having answers to them will make all the difference. They are: What problem are you trying to solve?
Do you have the necessary data to address the question, or do you need to generate the data?
How do you know what you want to know, and what assumptions are you willing to make?
How certain do you want to be, and do the results address the question you set out to answer?
What is your favorite society memory?
My favorite memory of the Society was when Dr. Lewis Sheiner complimented me on my paper, “Stability and Performance of a Population Pharmacokinetic Model”, at the ASCPT 1996 Annual Meeting.
Dr. Ette has been a member of ASCPT since 2008.
Welcome New Members of ASCPT!
Abdelrahman Moussa, BCh Alexandria University Precious Umeasalugo, BS Mark Davies, PhD Physiomics plc
Jaydeep Srimani, PhD
Daiichi Sankyo
Yue Han, PhD
US Food and Drug Administration
Hayley Close, BSc Physiomics plc Asia Wyatt, PhD
Boehringer Ingelheim International GmbH
Anindya Karmakar, MBBS, MD School of Tropical Medicine Angela Eakin, MD
Evolution Research Group
Mohammad Barary, MD
Shahid Beheshti University of Medical Sciences
William Hedrich, PhD
CSL Behring
Stephen Brandao Lotus Clinical Research Elizabeth Fazioli
Lotus Clinical Research Aparna Mohan Vantage Research
Ahmed Essam Abou Warda October 6 University Jumaimah Peer
University of the Witwatersrand
Sean Blackledge, PharmD
Stacey Luo, PharmD Astria Therapeutics Ghaith Mansour, PharmD Alfaisal University
Abena Dwamena, PharmD
Texas Tech University
Rajiv Balyan, PhD
Teva Pharmaceutical Industries Rosalin Arends, PhD MapLight Therapeutics
Guy Meno-Tetang, PhD
Kenji Miyazawa, PhD
Moderna Hongtao Yu, PhD AstraZeneca
Bo Zheng, PhD
Otsuka Pharmaceutical
Haifa Lyster, PhD, Royal Brompton & Harefield, Student/Trainee Holly George, RPh, Evolution Research Group, Full.
